« Return to News | Drug Sponsors | R&D Trends

Quotient, KWS partner in antimicrobial drug discovery

Tuesday, May 10, 2011 12:25 PM

Two U.K.-based providers of early-stage and other drug development services, Quotient Bioresearch and KWS BioTest, have partnered to offer coordinated “plate to patient” support for clients engaged in the discovery and development of new antimicrobial agents, according to Pharma Times.

As part of the agreement, Quotient and KWS will provide screening of anti-infectives from in vitro activity assays, efficacy testing and resistance profiling through to validated models of human disease, surveillance and clinical investigations.

The partnership will enable Quotient and KWS to carry out larger integrated studies in the sector.  

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.